ANI Pharmaceuticals Inc (ANIP) Receives Consensus Rating of “Hold” from Brokerages

Shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) have earned a consensus rating of “Hold” from the seven analysts that are covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $71.00.

Several equities research analysts recently issued reports on ANIP shares. TheStreet raised ANI Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Thursday, November 16th. Zacks Investment Research raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 price target on the stock in a research report on Tuesday, November 7th. ValuEngine raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 4th. Canaccord Genuity reissued a “buy” rating on shares of ANI Pharmaceuticals in a research report on Thursday, November 2nd. Finally, BidaskClub raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, January 5th.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Cortina Asset Management LLC acquired a new stake in ANI Pharmaceuticals in the fourth quarter worth $6,091,000. Rhumbline Advisers increased its position in ANI Pharmaceuticals by 16.5% in the fourth quarter. Rhumbline Advisers now owns 19,789 shares of the specialty pharmaceutical company’s stock worth $1,275,000 after buying an additional 2,807 shares during the period. Arizona State Retirement System increased its position in ANI Pharmaceuticals by 226.3% in the fourth quarter. Arizona State Retirement System now owns 15,061 shares of the specialty pharmaceutical company’s stock worth $971,000 after buying an additional 10,446 shares during the period. Intrust Bank NA increased its position in ANI Pharmaceuticals by 18.1% in the fourth quarter. Intrust Bank NA now owns 6,628 shares of the specialty pharmaceutical company’s stock worth $427,000 after buying an additional 1,018 shares during the period. Finally, Wells Fargo & Company MN increased its position in ANI Pharmaceuticals by 21.2% in the fourth quarter. Wells Fargo & Company MN now owns 13,588 shares of the specialty pharmaceutical company’s stock worth $876,000 after buying an additional 2,373 shares during the period. 53.51% of the stock is currently owned by hedge funds and other institutional investors.

Shares of ANI Pharmaceuticals (NASDAQ:ANIP) opened at $58.41 on Tuesday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 2.39 and a current ratio of 3.45. The stock has a market capitalization of $680.07, a P/E ratio of 92.71 and a beta of 2.79. ANI Pharmaceuticals has a 52-week low of $42.23 and a 52-week high of $74.70.

ILLEGAL ACTIVITY NOTICE: “ANI Pharmaceuticals Inc (ANIP) Receives Consensus Rating of “Hold” from Brokerages” was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2018/02/13/ani-pharmaceuticals-inc-anip-receives-consensus-rating-of-hold-from-brokerages.html.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply